Iteos Therapeutics S.A.
Records under this name other than the patents Iteos Therapeutics S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Back to Iteos Therapeutics S.A.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,995,101 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers Formerly held In force · High confidence | In force | High confidence | |
| US 10,329,349 | Anti-Tigit Antibodies Formerly held In force · High confidence | In force | High confidence | |
| US 11,439,705 | Anti-Tigit Antibodies Formerly held In force · High confidence | In force | High confidence | |
| US 11,427,594 | Non Brain Penetrant A2A Inhibitors and Methods for Use in the Treatment of Cancers Formerly held Lapsed on the fee record Ended Aug 30, 2026 · High confidence | Lapsed on the fee record | Ended Aug 30, 2026 | High confidence |
| US 11,376,255 | Thiocarbamate Derivatives as A2A Inhibitors, Pharmaceutical Composition Thereof and Combinations with Anticancer Agents Formerly held Lapsed on the fee record Ended Jul 5, 2026 · High confidence | Lapsed on the fee record | Ended Jul 5, 2026 | High confidence |
| US 9,949,951 | Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors Lapsed on the fee record Ended Apr 24, 2026 · USPTO record | Lapsed on the fee record | Ended Apr 24, 2026 | USPTO record |
| US 10,945,994 | Combinations Comprising a PYRROLIDINE-2,5-Dione IDO1 Inhibitor and an Anti-Body Lapsed on the fee record Ended Mar 16, 2025 · High confidence | Lapsed on the fee record | Ended Mar 16, 2025 | High confidence |
| US 10,398,679 | Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors Lapsed on the fee record Ended Sep 3, 2023 · USPTO record | Lapsed on the fee record | Ended Sep 3, 2023 | USPTO record |
| US 9,873,690 | Novel 3-Indol Substituted Derivatives, Pharmaceutical Compositions and Methods for Use Lapsed on the fee record Ended Jan 23, 2022 · High confidence | Lapsed on the fee record | Ended Jan 23, 2022 | High confidence |
| US 9,758,505 | 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use Lapsed on the fee record Ended Sep 12, 2021 · USPTO record | Lapsed on the fee record | Ended Sep 12, 2021 | USPTO record |